Paloma Partners’s MediciNova MNOV Stock Holding History

Paloma Partners’s Portfolio MNOV Stock Details MNOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,100	Closed	-$82K	–	1759
2019 Q4	$82K	Buy	+12,100	New	+$91K	﹤0.01%	2062
2018 Q1	–	Sell	-30,653	Closed	-$198K	–	2147
2017 Q4	$198K	Buy	+30,653	New	+$203K	﹤0.01%	1743

Other funds holding MNOV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Paloma Partners's MNOV Position: Q1 2020 in Review

Paloma Partners sold out of MediciNova (MNOV) in Q1 2020, closing a stake of 12,100 shares — an estimated $82K sold.

Paloma Partners first reported a position in MNOV in Q4 2017 and held it in 2 quarters. The position peaked at $198K in Q4 2017. 48 funds tracked by Wall St. Rank hold MNOV as of Q1 2020.

Paloma Partners reported no remaining MediciNova position as of Q1 2020 after selling out during the quarter.
Paloma Partners sold 12,100 MediciNova shares in Q1 2020, an estimated $82K.
Paloma Partners first reported a position in MediciNova in Q4 2017 and held it in 2 quarters.
Paloma Partners's MediciNova position peaked at $198K in Q4 2017.
48 funds tracked by Wall St. Rank held MediciNova as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.